Status: Recruiting
A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants with Active Ulcerative Colitis. The study aims to evaluate the safety, efficacy, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics of INT-210 in participants with active ulcerative colitis (UC).
Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Innatus Therapeutics (Shanghai) Co., Ltd.Updated: Jul 9, 2026Locations: 15
Eligibility criteria
Voluntarily participate in the study and sign the informed consent form (ICF); [+8]
Pregnant or lactating women, or those planning to become pregnant during the stu... [+33]